BACKGROUND Randomized trials support the use of transcatheter aortic valve replacement (TAVR) for the treatment
To date, 3 high-quality randomized controlled trials have supported the use of TAVR in intermediateand high-risk patients (6) (7) (8) , but these clinical trials excluded important groups of patients with higher risk comorbidities and were conducted at a select group of high-volume valve centers. Consequently, whether these results are applicable to clinical practice has been questioned (9) , and concerns regarding the safety and effectiveness of TAVR have been raised (10, 11) . These concerns are of increasing relevance because TAVR is applied to low-and intermediaterisk patients, in whom the risk of SAVR is less, and its long-term outcomes are well-documented (12) .
To address these lingering questions, we used observational data from 2 large U.S. procedural reg- Data for this analysis were drawn from 2 U.S. procedural registries: 1) SAVR data were drawn from the Society of Thoracic Surgeons (STS) National Database; and 2) TAVR data were drawn from the STS/American College of Cardiology TVT (Transcatheter Valve Therapy) Registry. The development and application of these registries have been described previously (13, 14) . More than 90% of cardiac surgery programs in the United States participate in the STS National Database, and participation in the TVT Registry is necessary for Medicare reimbursement. Notably, the involvement of a heart team is also necessary for Brennan et al. STATISTICAL ANALYSIS. An analytic sample was created using propensity score-based matching to correct for differences in characteristics of patients in the 2 registries. A propensity score, defined as the Values are median (interquartile range) or n (%), unless otherwise indicated. *A more complete listing of patient characteristics and standardized differences before and after propensity matching is included in the Online Appendix. †Anticoagulant agents include warfarin and novel oral anticoagulant agents.
CABG ¼ coronary artery bypass grafting; CAD ¼ coronary artery disease; CV ¼ cardiovascular; IABP ¼ intraaortic balloon pump; LVEF ¼ left ventricular ejection fraction; MI ¼ myocardial infarction; PA ¼ pulmonary artery; PCI ¼ percutaneous coronary intervention; SAVR ¼ surgical aortic valve replacement; STS PROM ¼ Society of Thoracic Surgeons Predicted Risk of Mortality; TAVR ¼ transcatheter aortic valve replacement.
probability of receiving TAVR given measured covariates, was calculated using logistic regression.
Detailed methods, including an extensive list of covariates identified by clinical input regarding factors thought to be related to both procedure selection and outcomes, and common to the 2 registries, are provided in Online Table 2 . Overlap in the covariate distribution and propensity scores between study groups was assessed. Because patients at the tails (<5% and >95%) of the propensity distribution were thought to represent subjects with an overwhelming likelihood of treatment with 1 or the other of the 2 treatments, these patients were excluded (Online Baseline characteristics of patients undergoing SAVR and TAVR were described and compared overall and within pre-specified subgroups on the basis of standardized differences (Online Figure 5 ).
Cox proportional hazard models were used to compare outcomes of TAVR versus SAVR by hazard ratios and 95% confidence intervals (CIs). DAOH was modeled as count data using generalized estimating equations with a log link and a fixed offset (adjusting for differential follow-up time) to obtain rate ratios and 95% CIs. Models for treatment on outcomes were fit to the matched sample using a robust empirical variance to account for within-hospital clustering. Associations were estimated in prespecified subgroups, along with 95% CIs and tests of interaction. Statistical significance was defined as p < 0.10, and significant values were evaluated for biological plausibility. All analyses were conducted using SAS version 9.4 (SAS Institute, Cary, North Carolina). The risk for stroke was highest in the first 30 days following treatment and was identical between TAVR and SAVR (2.8% vs. 2.8%; p ¼ 0.13) patients. An increase in the incidence of stroke was observed among TAVR (vs. SAVR) patients between 30 days and 1 year, with a progressive divergence of the stroke event curves. Nevertheless, the overall risk for stroke remained low during this interval (0.5% vs. Table 2) .
DISCUSSION
In a broad cohort of older U.S. patients with severe aortic stenosis who were eligible for treatment with either TAVR or SAVR, no significant difference was observed in death, stroke, or DAOH to 1 year. TAVR patients were more often discharged directly home, reflecting a less demanding post-operative recovery. Figure 7) . Subgroup results for stroke to 1 year are presented separately because of nonproportional hazards (Online Figure 8) . A balance of covariates within each subgroup was forced with inclusion of interaction terms in the propensity score. The p value for interaction represents the likelihood of interaction between the variable and the relative treatment effect. Comparative treatment effects were similar across most subgroups, with few significant interactions noted. CAD ¼ coronary artery disease; Dz ¼ disease; PA ¼ pulmonary artery; SAVR ¼ surgical aortic valve replacement;
TAVR ¼ transcatheter aortic valve replacement.
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